NAD+
Often discussed in relation to neuronal energy metabolism, fatigue, brain fog, and cognitive support.
View medication pageTherapy Hub
Mental Health
Mental health support therapies are frequently discussed around energy metabolism, cognition, social functioning, and stress response. This category includes compounds that appear in the literature for fatigue, brain fog, mood-related symptoms, or social-emotional regulation, but the evidence is still evolving and should be framed carefully as adjunctive and prescriber-directed.
Available Medications
Each medication below is grouped here because its mechanism, clinical use, or published literature helps explain why it fits this therapy category.
Oxytocin
Studied in anxiety, depression, PTSD, and social functioning because of its effects on social and stress-related neural circuitry.
View medication pageMore Medications Available
This is not a comprehensive list of our available medications. We have what you need.
Contact us for moreParoxetine
A non-hormonal SSRI option used in selected menopausal patients for vasomotor symptom support.
View medication page
Desvenlafaxine Succinate ER
An SNRI-based non-hormonal option used in selected menopausal patients for vasomotor symptom support.
View medication page
References
Studies, data, and supporting evidence
These references support the positioning statements used on this therapy hub. They are intended as educational source material for patients and prescribers, not as a substitute for individualized medical judgment.
Supplementation with NAD+ and Its Precursors to Prevent Cognitive Decline Across Disease Contexts
Review of NAD+ precursor supplementation across neurologic settings, supporting the rationale for cognitive and brain-energy positioning while underscoring that clinical data remain preliminary.
Full Text →Low-dose Paroxetine 7.5 mg for Menopausal Vasomotor Symptoms: Two Randomized Controlled Trials
Phase 3 trials found low-dose paroxetine reduced menopausal hot-flash burden versus placebo, supporting its role as a non-hormonal vasomotor symptom option.
PubMed →Effect and Safety of Paroxetine for Vasomotor Symptoms: Systematic Review and Meta-analysis
The meta-analysis found moderate-quality evidence that paroxetine reduces hot-flash frequency, while also highlighting common side effects such as nausea and dizziness.
PubMed →Desvenlafaxine for the Treatment of Vasomotor Symptoms Associated with Menopause
This randomized placebo-controlled trial showed desvenlafaxine improved menopausal vasomotor symptoms, supporting its positioning as a non-hormonal alternative when appropriate.
PubMed →